VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International […]